First Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan
This amendment updates the NeuroOne Medical Technologies Corporation 2021 Inducement Plan by increasing the total number of shares of common stock that may be issued under the plan to 570,350 shares. The change is effective as of November 9, 2023, and is made in accordance with the plan's provisions. The amendment ensures that the company can grant additional equity awards to eligible participants.
Exhibit 10.2
FIRST AMENDMENT TO
NEUROONE MEDICAL TECHNOLOGIES CORPORTAION
2021 INDUCEMENT PLAN
The NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the “Plan”) is hereby amended in the following respects, effective November 9, 2023, in accordance with Section 2(b)(vi) of the Plan.
The first sentence of Section 3(a) of the Plan is deleted in its entirety and replaced with the following sentence:
“Subject to Section 9(a) relating to Capitalization Adjustments, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will not exceed 570,350 shares (the “Share Reserve”).”
